{"id":"https://openalex.org/W4362546202","doi":"https://doi.org/10.1158/2326-6066.c.6548804.v1","title":"Data from Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti\u2013PD-L1 Immune Checkpoint Inhibitor","display_name":"Data from Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti\u2013PD-L1 Immune Checkpoint Inhibitor","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362546202","doi":"https://doi.org/10.1158/2326-6066.c.6548804.v1"},"language":"en","primary_location":{"id":"doi:10.1158/2326-6066.c.6548804.v1","doi":"https://doi.org/10.1158/2326-6066.c.6548804.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/2326-6066.c.6548804.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/2326-6066.c.6548804.v1","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5019318447","display_name":"Amanda J. Vandeveer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amanda J. Vandeveer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056309213","display_name":"Jonathan K. Fallon","orcid":"https://orcid.org/0000-0002-9762-2783","observed_orcids":["https://orcid.org/0000-0002-9762-2783"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jonathan K. Fallon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023615653","display_name":"Robert Tighe","orcid":"https://orcid.org/0009-0005-8406-0709","observed_orcids":["https://orcid.org/0009-0005-8406-0709"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert Tighe","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109110971","display_name":"Helen Sabzevari","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Helen Sabzevari","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059931764","display_name":"Jeffrey Schlom","orcid":"https://orcid.org/0000-0001-7932-4072","observed_orcids":["https://orcid.org/0000-0001-7932-4072"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeffrey Schlom","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5110820942","display_name":"John W. Greiner","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John W. Greiner","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.888700008392334,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.888700008392334,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.1080000028014183,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/avelumab","display_name":"avelumab","score":0.9940000176429749},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.9589999914169312},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7649999856948853},{"id":"https://openalex.org/keywords/non-muscle-invasive-bladder-cancer","display_name":"non-muscle-invasive bladder cancer","score":0.9909999966621399},{"id":"https://openalex.org/keywords/urothelial-carcinoma","display_name":"urothelial carcinoma","score":0.9890000224113464},{"id":"https://openalex.org/keywords/carcinoma-in-situ","display_name":"carcinoma in situ","score":0.8529999852180481},{"id":"https://openalex.org/keywords/bcg","display_name":"BCG","score":0.7239999771118164},{"id":"https://openalex.org/keywords/cd4-t-cells","display_name":"CD4+ T cells","score":0.8989999890327454},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.9210000038146973},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.8149999976158142},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.7720000147819519},{"id":"https://openalex.org/keywords/tumor-immune-evasion","display_name":"tumor immune evasion","score":0.5699999928474426}],"concepts":[{"id":"https://openalex.org/C2777381376","wikidata":"https://www.wikidata.org/wiki/Q21083261","display_name":"Avelumab","level":5,"score":0.845911979675293},{"id":"https://openalex.org/C2780352672","wikidata":"https://www.wikidata.org/wiki/Q504775","display_name":"Bladder cancer","level":3,"score":0.7075629830360413},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6278201937675476},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5920231938362122},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5642068386077881},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5157809257507324},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4750242829322815},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.4408890902996063},{"id":"https://openalex.org/C2778326572","wikidata":"https://www.wikidata.org/wiki/Q7852668","display_name":"Tumor-infiltrating lymphocytes","level":4,"score":0.415409654378891},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.4131760597229004},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4055710434913635},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3277548551559448},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.23963963985443115},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.18165799975395203}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/2326-6066.c.6548804.v1","doi":"https://doi.org/10.1158/2326-6066.c.6548804.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/2326-6066.c.6548804.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/2326-6066.c.6548804.v1","doi":"https://doi.org/10.1158/2326-6066.c.6548804.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/2326-6066.c.6548804.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2274704822","https://openalex.org/W4393096252","https://openalex.org/W2185513286","https://openalex.org/W2892779818","https://openalex.org/W2099786413","https://openalex.org/W4225249000","https://openalex.org/W4205365572","https://openalex.org/W3116009038","https://openalex.org/W4393281521","https://openalex.org/W2532217238"],"abstract_inverted_index":{"Abstract":[0],"Bacillus":[1],"Calmette\u2013Guerin":[2],"(BCG)":[3],"is":[4,29],"the":[5,24,53,70,73,105,122,126,142,163,190,238],"standard":[6],"of":[7,39,47,52,72,75,108,125,129,144,165,189,223],"care":[8],"for":[9,12,81,141,226,240],"intravesical":[10],"therapy":[11],"carcinoma":[13,227],"in":[14,63,174,183,201,228],"situ":[15,229],"and":[16,42,59,77,146,220,230],"non-muscle":[17,130,231],"invasive,":[18,131,232],"nonmetastatic":[19,132,233],"human":[20],"urothelial":[21,133,234],"carcinoma.":[22],"Although":[23],"responsiveness":[25],"to":[26,31,103,112,213,236],"this":[27,85,184],"immunotherapeutic":[28],"believed":[30],"be":[32,211],"linked":[33],"with":[34,98],"(i)":[35],"a":[36,44,195],"high":[37],"number":[38,46],"somatic":[40],"mutations":[41],"(ii)":[43],"large":[45],"tumor-infiltrating":[48],"lymphocytes,":[49],"recent":[50],"findings":[51,180],"roles":[54],"that":[55,182],"inhibitory":[56],"immune":[57,176,198,218],"receptors":[58],"their":[60],"ligands":[61],"play":[62],"tumor":[64,95,116,186,204,208],"evasion":[65],"may":[66],"provide":[67,237],"insights":[68],"into":[69],"limitations":[71],"effectiveness":[74],"BCG":[76],"offer":[78],"new":[79],"targets":[80],"immune-based":[82,224],"therapy.":[83],"In":[84],"study,":[86],"an":[87,110],"aggressive,":[88],"bioluminescent":[89],"orthotopic":[90],"bladder":[91,127,136,185,207],"cancer":[92],"model,":[93,187],"MB49":[94],"cells":[96,117],"transfected":[97],"luciferase":[99],"(MB49luc),":[100],"was":[101],"used":[102,212],"study":[104],"antitumor":[106,154,157,217],"effects":[107,158],"avelumab,":[109],"antibody":[111],"PD-L1.":[113],"MB49luc":[114,135],"murine":[115],"form":[118],"multifocal":[119],"tumors":[120,137],"on":[121,162],"mucosal":[123],"wall":[124],"reminiscent":[128],"carcinomas.":[134],"are":[138],"highly":[139],"positive":[140],"expression":[143],"PD-L1,":[145],"avelumab":[147],"administration":[148],"induced":[149],"significant":[150],"(P":[151],"<":[152],"0.05)":[153],"effects.":[155],"These":[156],"were":[159],"more":[160],"dependent":[161],"presence":[164],"CD4":[166],"than":[167],"CD8":[168],"T":[169],"cells,":[170],"as":[171],"determined":[172],"by":[173],"vivo":[175],"cell":[177],"depletions.":[178],"The":[179],"suggest":[181],"interruption":[188],"immune-suppressive":[191],"PD-1/PD-L1":[192],"complex":[193],"releases":[194],"local":[196],"adaptive":[197],"response":[199],"that,":[200],"turn,":[202],"reduces":[203],"growth.":[205],"This":[206],"model":[209],"can":[210],"further":[214],"identify":[215],"host":[216],"mechanisms":[219],"evaluate":[221],"combinations":[222],"therapies":[225],"carcinoma,":[235],"rationale":[239],"subsequent":[241],"clinical":[242],"studies.":[243],"Cancer":[244],"Immunol":[245],"Res;":[246],"4(5);":[247],"452\u201362.":[248],"\u00a92016":[249],"AACR.":[250]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2023-04-06T00:00:00"}